Evidence map›Paper›PMID 23711722›Full record

ArticleAnalytical biochemistry2013

Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore.

Eric S Day, Allan D Capili, Christopher W Borysenko, Mohammad Zafari, Adrian Whitty

Open access · greenAbstract read
In one paragraph

Article in Analytical biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eric S DayBiogen Idec, Cambridge, MA 02142, USA. estevenday@gmail.com
Allan D Capili
Christopher W Borysenko
Mohammad Zafari
Adrian Whitty
Biogen (United States) · USBoston University · US

Funding

Design of Macrocyclic Inhibitors of the NEMO/IKKa/b Protein-Protein InteractionR01GM094551 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WHITTY, ADRIAN · 2010 to 2013
$1.7M
Quantitative Analysis of RET Receptor Activation and SignalingR01GM087469 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WHITTY, ADRIAN · 2010 to 2013
$1.2M
NIGMS NIH HHS GM087469NIGMS NIH HHS GM094551NIGMS NIH HHS R01 GM087469NIGMS NIH HHS R01 GM094551
6 · The paper itself

Abstract

We describe a general Biacore method for measuring equilibrium binding affinities and stoichiometries for interactions between unmodified proteins and their unmodified ligands free in solution. Mixtures of protein and ligand are preequilibrated at different ratios in solution and then analyzed by Biacore using a sensor chip surface that detects only unbound analyte. Performing the Biacore analysis under mass transport limited conditions allows the concentration of unbound analyte to be determined from the initial velocity of binding. Plots of initial velocity versus the concentration of the varied binding partner are fitted to a quadratic binding equation to give the affinity and stoichiometry of binding. We demonstrate the method using soluble Her2 extracellular domain binding to monovalent, bivalent, and trivalent forms of an anti-Her2 antibody. The affinity we measured agrees with that obtained from conventional Biacore kinetic analysis, and the stoichiometries for the resulting 1:1, 1:2, and 1:3 complexes were confirmed by gel filtration with in-line light scattering. The method is applicable over an affinity range of approximately 100 pM to 1 μM and is particularly useful when there is concern that covalently modifying one or the other binding partner might affect its binding properties or where multivalency might otherwise complicate a quantitative analysis of binding.

Indexed as

AnimalsChromatography, GelCricetinaeCricetulusErb-b2 Receptor Tyrosine KinasesHumansKineticsProtein BindingProteinsSurface Plasmon ResonanceErb-b2 Receptor Tyrosine KinasesProteinsAffinityMass transportMultivalencySolution bindingStoichiometrySurface plasmon resonance

Identifiers

PMID23711722
PMCPMC8627677
OpenAlexW2019926384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.